Owen O’Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAH
Owen O’Connor
Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York
Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other targeting the mTOR signaling pathway with a drug called temsirolimus.
[audio:https://www.audiomedica.com/podcasting/ash2005/Owen_O_Connor_2.mp3]